Scholarlink

Background <p>Psoriasis is a chronic immune-mediated inflammatory skin disease characterized by keratinocyte hyperproliferation and regulation of inflammatory cytokines. Conventional therapies have limited clinical management due to inadequate therapeutic efficacy and systemic side effects. Therefore, there is a critical need for safer and more effective targeted therapeutic strategies.</p> Purpose <p>The current study aimed to develop chrysin (ChRy)-loaded lipid-polymer hybrid nanoparticles (HNPs) based hydrogel to enhance the therapeutic efficacy of chrysin in an imiquimod-induced psoriasis rat model.</p> Methods <p>ChRy-HNPs were prepared using the emulsification solvent evaporation method and optimized using the Box-Behnken Design. Furthermore, the optimized nanoformulation was embedded in a hydrogel and evaluated for in vivo anti-psoriatic efficacy.</p> Results <p>The optimized ChRy-HNPs were spherical with an average particle size of 187.23&#xa0;nm, entrapment efficiency of 97.33%, drug loading of 2.88%, and good colloidal stability with a negative zeta potential. In vitro drug release study of the optimized ChRy-HNPs followed the Higuchi model, achieving controlled release for up to 48&#xa0;h. Optimized ChRy-HNPs exhibited remarkable cytotoxic effects on A-431 cells, enhanced cellular uptake, inhibited the inflammatory cytokine IL-17A, and restored IL-4 levels. The ChRy-HNP-hydrogel achieved pronounced skin permeability and enhanced in vivo anti-psoriatic therapeutic efficacy, confirming its superior anti-psoriatic effect over the standard formulation and free chrysin.</p> Conclusion <p>Our findings suggest that the optimized chrysin-loaded hybrid nanoparticles have potential therapeutic efficacy and offer an excellent nanomedicine for the management of psoriasis.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Chrysin-Loaded Hybrid Nanoparticles for Enhanced Anti-Psoriatic Activity in Imiquimod-Induced Psoriasis Rat Model

  • 期刊论文

  • 发表日期：

    2026年4月15日

查看全文
  • Taison Jamatia,
  • Malay K. Das,
  • Sentu Das,
  • Balisa Mosisa Ejeta

摘要

Background

Psoriasis is a chronic immune-mediated inflammatory skin disease characterized by keratinocyte hyperproliferation and regulation of inflammatory cytokines. Conventional therapies have limited clinical management due to inadequate therapeutic efficacy and systemic side effects. Therefore, there is a critical need for safer and more effective targeted therapeutic strategies.

Purpose

The current study aimed to develop chrysin (ChRy)-loaded lipid-polymer hybrid nanoparticles (HNPs) based hydrogel to enhance the therapeutic efficacy of chrysin in an imiquimod-induced psoriasis rat model.

Methods

ChRy-HNPs were prepared using the emulsification solvent evaporation method and optimized using the Box-Behnken Design. Furthermore, the optimized nanoformulation was embedded in a hydrogel and evaluated for in vivo anti-psoriatic efficacy.

Results

The optimized ChRy-HNPs were spherical with an average particle size of 187.23 nm, entrapment efficiency of 97.33%, drug loading of 2.88%, and good colloidal stability with a negative zeta potential. In vitro drug release study of the optimized ChRy-HNPs followed the Higuchi model, achieving controlled release for up to 48 h. Optimized ChRy-HNPs exhibited remarkable cytotoxic effects on A-431 cells, enhanced cellular uptake, inhibited the inflammatory cytokine IL-17A, and restored IL-4 levels. The ChRy-HNP-hydrogel achieved pronounced skin permeability and enhanced in vivo anti-psoriatic therapeutic efficacy, confirming its superior anti-psoriatic effect over the standard formulation and free chrysin.

Conclusion

Our findings suggest that the optimized chrysin-loaded hybrid nanoparticles have potential therapeutic efficacy and offer an excellent nanomedicine for the management of psoriasis.